In this study, Gutkind and colleagues found that the cost per participant decreases with higher caseloads in real-world settings compared to costs incurred in the intervention trial. In a sensitivity analysis, maintaining a site’s peak caseload during the trial (approximately 5 participants per week on average) was found to lower the cost per participant by a half, from $450 to $220 in 2017 USD. When adapting to a real-world setting with a maximum of 10 cases per week, the cost each week per participant lowered by three quarters, from $450 to $110 in 2017 USD. Co-authors also found the average start-up cost for HCV care facilitation to be approximately $6,320 per trial site. Costs could be further reduced by adapting administrative and recruitment processes for real-world settings, such as maximizing outreach activities through site visitations and database search records, reducing the number of supervision meetings, and leveraging local staff and webinars to conduct start-up trainings.